19.28
price down icon1.78%   -0.35
after-market Dopo l'orario di chiusura: 19.25 -0.03 -0.16%
loading
Precedente Chiudi:
$19.63
Aprire:
$19.7
Volume 24 ore:
410.43K
Relative Volume:
0.48
Capitalizzazione di mercato:
$227.05M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-1.7123
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
-1.83%
1M Prestazione:
+8.80%
6M Prestazione:
-44.18%
1 anno Prestazione:
-15.77%
Intervallo 1D:
Value
$19.10
$20.56
Intervallo di 1 settimana:
Value
$18.59
$20.56
Portata 52W:
Value
$7.31
$130.00

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name
Nome
Tonix Pharmaceuticals Holding Corp
Name
Telefono
212-980-9155
Name
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Name
Dipendente
81
Name
Cinguettio
@TONIXPharma
Name
Prossima data di guadagno
2025-03-17
Name
Ultimi documenti SEC
Name
TNXP's Discussions on Twitter

Confronta TNXP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TNXP
Tonix Pharmaceuticals Holding Corp
19.28 231.17M 0 -121.02M -114.09M -11.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-04-18 Iniziato Noble Capital Markets Outperform
2019-04-18 Aggiornamento ROTH Capital Neutral → Buy
2017-08-18 Aggiornamento ROTH Capital Neutral → Buy
2016-09-07 Downgrade ROTH Capital Buy → Neutral
2016-02-17 Reiterato Oppenheimer Outperform
2015-11-04 Iniziato Cantor Fitzgerald Buy
2015-06-12 Iniziato Oppenheimer Outperform
2015-02-17 Reiterato ROTH Capital Buy
2014-09-29 Reiterato ROTH Capital Buy
Mostra tutto

Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie

pulisher
Dec 11, 2025

Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel Amid Key Commercialization Phase - citybuzz

Dec 10, 2025
pulisher
Dec 09, 2025

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel - citybiz

Dec 09, 2025
pulisher
Dec 08, 2025

TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya - Smartkarma

Dec 08, 2025
pulisher
Dec 08, 2025

TNXP: Tonix Now a Commercial Stage Company Following the Launch of Tonmya™ - Yahoo Finance

Dec 08, 2025
pulisher
Dec 07, 2025

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals - ts2.tech

Dec 07, 2025
pulisher
Dec 04, 2025

Is Tonix Pharmaceuticals Holding Corp. stock ready for breakout - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Tonix receives FDA clearance to launch phase 2 trial for major depressive disorder - Proactive financial news

Dec 03, 2025
pulisher
Dec 03, 2025

Is Tonix Pharmaceuticals Holding Corp. stock positioned well for digital economy2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Tonix reports positive results in TNX-1500 phase 1 trial - MSN

Dec 02, 2025
pulisher
Dec 01, 2025

Tonix Pharmaceuticals (TNXP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 01, 2025
pulisher
Dec 01, 2025

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely? - Sahm

Dec 01, 2025
pulisher
Nov 28, 2025

Aug Drivers: Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail traders2025 Price Targets & Weekly Watchlist for Hot Stocks - moha.gov.vn

Nov 28, 2025
pulisher
Nov 27, 2025

Why analysts remain bullish on Tonix Pharmaceuticals Holding Corp. stockCPI Data & Daily Volume Surge Signals - moha.gov.vn

Nov 27, 2025
pulisher
Nov 27, 2025

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN

Nov 27, 2025
pulisher
Nov 26, 2025

What drives Tonix Pharmaceuticals Holding Corp stock priceTake Profit Strategies & Free Daily Top Stock Picks for All Investors - earlytimes.in

Nov 26, 2025
pulisher
Nov 24, 2025

Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP) - Seeking Alpha

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals launches TONMYA, a first-in-class non-opioid Fibromyalgia therapy - Proactive financial news

Nov 24, 2025
pulisher
Nov 24, 2025

FDA clears IND for Tonix’s depression treatment candidate By Investing.com - Investing.com Nigeria

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts - TipRanks

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals (TNXP) Secures FDA Clearance for Depressio - GuruFocus

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix To Initiate Phase 2 Trial Of TNX-102 SL For Major Depressive Disorder In Mid-2026 - RTTNews

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals gets FDA clearance to develop TNX-102 for depression - Seeking Alpha

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals announces FDA IND clearance for phase 2 study of TNX-102 SL - MarketScreener

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl - TradingView

Nov 24, 2025
pulisher
Nov 24, 2025

Pharmaceuticals Receives FDA Clearance to Proceed With Phase 2 Study of TNX-102 SL for Major Depressive Disorder - MarketScreener

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals (TNXP) Advances with FDA IND Clearance for Depression Treatment - GuruFocus

Nov 24, 2025
pulisher
Nov 24, 2025

FDA clears IND for Tonix’s depression treatment candidate - Investing.com India

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder - The Manila Times

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharmaceuticals to Advance TNX-102 SL into Pivotal Phase 2 Study for Major Depressive Disorder Following IND Clearance from FDA - Quiver Quantitative

Nov 24, 2025
pulisher
Nov 24, 2025

Tonix Pharma (Nasdaq: TNXP) cleared to start Phase 2 HORIZON MDD study of TNX-102 SL - Stock Titan

Nov 24, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals increases stock offering capacity to $400 million By Investing.com - Investing.com Nigeria

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals increases stock offering capacity to $400 million - Investing.com

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharma Amends Sales Agreement to Raise Capital - TipRanks

Nov 21, 2025
pulisher
Nov 21, 2025

Tonix Pharmaceuticals amends sales agreement with Alliance Global PartnersSEC filing - MarketScreener

Nov 21, 2025
pulisher
Nov 21, 2025

Will Tonix Pharmaceuticals Holding Corp. stock split again soonEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Can Tonix Pharmaceuticals Holding Corp. stock resist market sell offs2025 Big Picture & Long-Term Capital Growth Ideas - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesCEO Change & Short-Term High Return Ideas - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.Entry Point & Step-by-Step Swing Trade Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueOil Prices & Consistent Growth Equity Picks - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 19, 2025
pulisher
Nov 18, 2025

Tonix Pharma Expands Share Repurchase Program - TipRanks

Nov 18, 2025
pulisher
Nov 18, 2025

Tonix Pharmaceuticalsincreases share repurchase program to $35 millionSEC filing - MarketScreener

Nov 18, 2025
pulisher
Nov 18, 2025

[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan

Nov 18, 2025
pulisher
Nov 18, 2025

Tonix Pharmaceuticals Expands Share Repurchase Program - TradingView

Nov 18, 2025
pulisher
Nov 18, 2025

Real time alert setup for Tonix Pharmaceuticals Holding Corp. performance2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com

Nov 18, 2025

Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Capitalizzazione:     |  Volume (24 ore):